No Data
Haixiang Pharmaceutical: 2024 Annual Results Forecast
Zhejiang Hisoar Pharmaceutical (002099.SZ): Expected losses of 0.25 billion yuan to -0.35 billion yuan in 2024.
Glounhui January 21丨Zhejiang Hisoar Pharmaceutical (002099.SZ) announced that it expects a loss of 250 million to -350 million yuan in 2024, with a non-recurring loss of 270 million to -390 million yuan. 1. In accordance with enterprise accounting standards and relevant regulations of the company's accounting policies, and based on the principle of prudence, the company conducted impairment tests on various assets within the scope of the consolidated financial statements as of December 31, 2024, and provided impairment provisions for assets that may suffer impairment losses. For the year 2024, a total provision for fixed asset impairment and goodwill impairment is proposed to be 230 million yuan to 30.
Zhejiang hisoar pharmaceutical (002099.SZ): The associate company Huayi Taikang has been approved to be listed on the national equities exchange and quotations.
Grain Alliance December 2nd | Zhejiang Hisoar Pharmaceutical (002099.SZ) announced that the company's 1.85% stake in the affiliated company Huayitai Kang Pharmaceutical Co., Ltd. (hereinafter referred to as "Huayitai Kang") recently received a letter of consent from the National Equities Exchange and Quotations System Limited Liability Company regarding the public transfer of Huayitai Kang Pharmaceutical Co., Ltd. shares and listing on the National Equities Exchange and Quotations System ('New Third Board'), with the trading method being the call auction trading. Huayitai Kang application
Zhejiang Hisoar Pharmaceutical (002099.SZ): The company's dye sector sales in the first to third quarters have slightly increased compared to last year.
Gridsum November 27th | zhejiang hisoar pharmaceutical (002099.SZ) stated in recent investor relations activities that there is currently no sign of a recovery trend in the dye industry cycle. The company's dye sector saw a slight increase in sales volume in the first three quarters compared to the same period last year. The company is actively expanding into emerging areas such as digital inkjet printing, high-performance dye pigments, liquid crystals, etc., to promote the high-quality upgrade of the company's industrial chain and enhance the company's industry competitiveness.
Zhejiang hisoar pharmaceutical (002099.SZ): The peptide platform project has successfully integrated into the industry chain supporting original research pharmaceutical companies and has achieved partial product commercialization supply.
GeLongHui, November 27th | zhejiang hisoar pharmaceutical (002099.SZ) stated in recent investor relations activities that the company's polypeptide platform project has successfully entered the original drug enterprise supporting industry chain and achieved partial commercial supply of products. The company will continue to expand new project verification cooperation, promote domestic and foreign collaborations with other pharmaceutical companies, and increase product market share.
Zhejiang Hisoar Pharmaceutical (002099.SZ): The customer validation batch of non-sterile active pharmaceutical ingredient project for Peinan original research has been delivered.
On November 27, Gelonghui reported that zhejiang hisoar pharmaceutical (002099.SZ) recently stated in an investor relations activity that the company is maintaining a "production-end advantage + BD-end expansion" dual-driver development in the CMO/CDMO business. There is a good growth momentum for existing products with strategic cooperative customers, and the pace of new project integration is continuously accelerating. The non-sterile active pharmaceutical ingredient project for the Peinan original research client has completed the verification batch delivery, and the company is assisting the client with global market certification; additionally, other anti-infection projects are in the verification batch stage.
Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) Shares May Have Slumped 32% But Getting In Cheap Is Still Unlikely
